title: Identification of potential synthetic lethal genes to p53 using a computational biology approach.
abstract: BACKGROUND
  Identification of genes that are synthetic lethal to p53 is an important strategy for anticancer therapy as p53 mutations have been reported to occur in more than half of all human cancer cases. Although genome-wide RNAi screening is an effective approach to finding synthetic lethal genes, it is costly and labor-intensive.
  
  
  METHODS
  To illustrate this approach, we identified potentially druggable genes synthetically lethal for p53 using three microarray datasets for gene expression profiles of the NCI-60 cancer cell lines, one next-generation sequencing (RNA-Seq) dataset from the Cancer Genome Atlas (TCGA) project, and one gene expression data from the Cancer Cell Line Encyclopedia (CCLE) project. We selected the genes which encoded kinases and had significantly higher expression in the tumors with functional p53 mutations (somatic mutations) than in the tumors without functional p53 mutations as the candidates of druggable synthetic lethal genes for p53. We identified important regulatory networks and functional categories pertinent to these genes, and performed an extensive survey of literature to find experimental evidence that support the synthetic lethality relationships between the genes identified and p53. We also examined the drug sensitivity difference between NCI-60 cell lines with functional p53 mutations and NCI-60 cell lines without functional p53 mutations for the compounds that target the kinases encoded by the genes identified.
  
  
  RESULTS
  Our results indicated that some of the candidate genes we identified had been experimentally verified to be synthetic lethal for p53 and promising targets for anticancer therapy while some other genes were putative targets for development of cancer therapeutic agents.
  
  
  CONCLUSIONS
  Our study indicated that pre-screening of potential synthetic lethal genes using gene expression profiles is a promising approach for improving the efficiency of synthetic lethal RNAi screening.
authors.affiliation: Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE, USA. xiaosheng.wang@unmc.edu.
authors.forename: Xiaosheng
authors.initials: X
authors.lastname: Wang
authors.forename: Richard
authors.initials: R
authors.lastname: Simon
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D002453:Cell Cycle / Q000235:genetics; D045744:Cell Line, Tumor; D019295:Computational Biology; D020869:Gene Expression Profiling; D020868:Gene Silencing; D005804:Genes, Lethal / Q000235:genetics*; D006801:Humans; D058990:Molecular Targeted Therapy; D009154:Mutation; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D016159:Tumor Suppressor Protein p53
references.citation: Oncogene. 2004 May 27;23(25):4430-43
references.pmid: 15077194
references.citation: Am J Hum Genet. 2003 Mar;72(3):691-703
references.pmid: 12529853
references.citation: Mol Cancer. 2009 Feb 13;8:8
references.pmid: 19216791
references.citation: Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8302-5
references.pmid: 10890907
references.citation: Cancer Lett. 2006 Apr 8;235(1):1-10
references.pmid: 15907369
references.citation: Cancer Cell. 2006 Sep;10(3):191-202
references.pmid: 16959611
references.citation: Science. 1991 Jul 5;253(5015):49-53
references.pmid: 1905840
references.citation: Mol Cancer Ther. 2010 Feb;9(2):268-78
references.pmid: 20124450
references.citation: Head Neck. 2007 Mar;29(3):272-84
references.pmid: 17230559
references.citation: Mutat Res. 2003 Nov 27;532(1-2):29-40
references.pmid: 14643427
references.citation: Oncogene. 2007 Jan 25;26(4):509-20
references.pmid: 16862181
references.citation: Curr Opin Pharmacol. 2003 Aug;3(4):371-7
references.pmid: 12901945
references.citation: Biochim Biophys Acta. 2013 Feb;1834(2):508-15
references.pmid: 23201157
references.citation: Oral Oncol. 2011 Jan;47(1):8-15
references.pmid: 21109480
references.citation: FASEB J. 2000 Nov;14(14):2147-57
references.pmid: 11053235
references.citation: J Clin Oncol. 2009 May 1;27(13):2278-87
references.pmid: 19332717
references.citation: Cold Spring Harb Perspect Biol. 2010 Feb;2(2):a001057
references.pmid: 20182617
references.citation: Cancer Biol Ther. 2009 Apr;8(7):645-7
references.pmid: 19270499
references.citation: Hum Genet. 2010 Dec;128(6):567-75
references.pmid: 20976469
references.citation: Mol Biosyst. 2010 Jan;6(1):17-29
references.pmid: 20024063
references.citation: Cancer Res. 2006 Jun 15;66(12):6319-26
references.pmid: 16778209
references.citation: Nature. 2007 Feb 8;445(7128):661-5
references.pmid: 17251932
references.citation: Nat Med. 2002 Mar;8(3):282-8
references.pmid: 11875500
references.citation: EMBO J. 1997 Aug 15;16(16):4973-82
references.pmid: 9305639
references.citation: Oncogene. 2007 Apr 2;26(15):2202-11
references.pmid: 17401429
references.citation: Horm Cancer. 2011 Apr;2(2):113-6
references.pmid: 21475725
references.citation: Oncogene. 2011 Aug 11;30(32):3477-88
references.pmid: 21577205
references.citation: Mol Cell Biol. 2009 Jun;29(11):2935-44
references.pmid: 19332559
references.citation: Mol Cancer. 2009 Dec 31;8:131
references.pmid: 20042122
references.citation: Dev Cell. 2007 Aug;13(2):190-202
references.pmid: 17681131
references.citation: Nat Cell Biol. 2011 Jun 05;13(7):809-18
references.pmid: 21642980
references.citation: Haematologica. 2011 May;96(5):672-80
references.pmid: 21242189
references.citation: Nat Chem Biol. 2012 Jul;8(7):646-54
references.pmid: 22660439
references.citation: Neurology. 1995 Aug;45(8):1533-9
references.pmid: 7644054
references.citation: Cancer Biol Ther. 2004 Feb;3(2):156-61
references.pmid: 14764989
references.citation: Nat Rev Cancer. 2007 Jul;7(7):554-62
references.pmid: 17585335
references.citation: Nat Struct Mol Biol. 2011 Jun;18(6):721-7
references.pmid: 21552262
references.citation: Proc Natl Acad Sci U S A. 1989 Apr;86(7):2403-7
references.pmid: 2648401
references.citation: Genes Dev. 2004 Aug 15;18(16):1926-45
references.pmid: 15314020
references.citation: Nat Rev Mol Cell Biol. 2004 Jun;5(6):429-40
references.pmid: 15173822
references.citation: J Cell Biol. 2011 Sep 5;194(5):737-50
references.pmid: 21875946
references.citation: Clin Cancer Res. 2006 Mar 1;12(5):1647-53
references.pmid: 16533793
references.citation: Nat Commun. 2013;4:1775
references.pmid: 23653187
references.citation: Cell Cycle. 2010 Mar 1;9(5):870-9
references.pmid: 20160511
references.citation: Cancer Res. 2005 Dec 1;65(23):11034-43
references.pmid: 16322253
references.citation: Proc Natl Acad Sci U S A. 2007 May 15;104(20):8334-9
references.pmid: 17488820
references.citation: Mol Cell Biol. 2012 Feb;32(4):868-79
references.pmid: 22184064
references.citation: Biochem Res Int. 2012;2012:195903
references.pmid: 22852086
references.citation: PLoS One. 2012;7(7):e41413
references.pmid: 22848487
references.citation: Am J Pathol. 2010 Oct;177(4):2034-45
references.pmid: 20724597
references.citation: Nat Med. 2011 Nov 20;17(12):1646-51
references.pmid: 22101766
references.citation: Mol Syst Biol. 2005;1:2005.0022
references.pmid: 16729057
references.citation: Mol Cancer Ther. 2010 Jul;9(7):2079-89
references.pmid: 20571075
references.citation: Arch Biochem Biophys. 2002 Mar 1;399(1):1-5
references.pmid: 11883897
references.citation: Nature. 1994 Jun 23;369(6482):678-82
references.pmid: 8208298
references.citation: Adv Cancer Res. 2007;97:321-38
references.pmid: 17419952
references.citation: Cancer Biol Ther. 2004 Mar;3(3):305-13
references.pmid: 14726685
references.citation: Oncogene. 2000 Jul 27;19(32):3656-64
references.pmid: 10951572
references.citation: Cell. 1988 May 20;53(4):549-54
references.pmid: 2453289
references.citation: Mol Carcinog. 2006 Jan;45(1):26-37
references.pmid: 16267831
references.citation: Neoplasia. 2008 Sep;10(9):920-31
references.pmid: 18714392
references.citation: PLoS One. 2009 Nov 12;4(11):e7819
references.pmid: 19915674
references.citation: J Biol Chem. 1998 Oct 30;273(44):29066-71
references.pmid: 9786912
references.citation: Cell. 2009 May 29;137(5):835-48
references.pmid: 19490893
references.citation: Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8204-9
references.pmid: 15928081
references.citation: Breast Cancer Res. 2007;9(3):R30
references.pmid: 17504517
references.citation: Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3964-9
references.pmid: 19225112
references.citation: Br J Cancer. 2009 Apr 21;100(8):1213-8
references.pmid: 19319136
references.citation: Nat Rev Cancer. 2005 Sep;5(9):689-98
references.pmid: 16110319
references.citation: Biol Cell. 2004 Apr;96(3):215-29
references.pmid: 15182704
references.citation: Cancer Inform. 2007 Feb 04;3:11-7
references.pmid: 19455231
references.citation: BMC Cancer. 2006 Dec 06;6:276
references.pmid: 17150101
references.citation: J Biol Chem. 2006 Sep 1;281(35):25134-42
references.pmid: 16798743
references.citation: BMC Genomics. 2009 Jun 23;10:277
references.pmid: 19549304
references.citation: Cancer Res. 2012 Jul 15;72(14):3499-511
references.pmid: 22802077
references.citation: Oncogene. 1996 Dec 5;13(11):2477-82
references.pmid: 8957091
references.citation: Curr Mol Med. 2008 Dec;8(8):774-83
references.pmid: 19075675
references.citation: Curr Biol. 2007 Feb 20;17(4):304-15
references.pmid: 17291761
references.citation: Int J Biochem Cell Biol. 2008;40(9):1753-63
references.pmid: 18296102
references.citation: Cancer Res. 2004 Oct 1;64(19):7110-6
references.pmid: 15466207
references.citation: Proc Natl Acad Sci U S A. 2003 May 13;100(10):5789-94
references.pmid: 12732729